These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34463131)

  • 1. Biopharmaceutical quality control with mass spectrometry.
    Liu S; Schulz BL
    Bioanalysis; 2021 Aug; 13(16):1275-1291. PubMed ID: 34463131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent applications of quantitative mass spectrometry in biopharmaceutical process development and manufacturing.
    Li X
    J Pharm Biomed Anal; 2023 Sep; 234():115581. PubMed ID: 37494866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mass spectrometry in the characterization of biologic protein products.
    Rathore D; Faustino A; Schiel J; Pang E; Boyne M; Rogstad S
    Expert Rev Proteomics; 2018 May; 15(5):431-449. PubMed ID: 29694790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.
    Kaltashov IA; Bobst CE; Abzalimov RR; Berkowitz SA; Houde D
    J Am Soc Mass Spectrom; 2010 Mar; 21(3):323-37. PubMed ID: 19963397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
    Bobst CE; Kaltashov IA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1517-29. PubMed ID: 21542797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.
    Kaltashov IA; Bobst CE; Abzalimov RR; Wang G; Baykal B; Wang S
    Biotechnol Adv; 2012; 30(1):210-22. PubMed ID: 21619926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.
    Kaltashov IA; Bobst CE; Pawlowski J; Wang G
    J Pharm Biomed Anal; 2020 May; 184():113169. PubMed ID: 32092629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in LC-MS based characterization of protein-based bio-therapeutics - mastering analytical challenges posed by the increasing format complexity.
    Graf T; Heinrich K; Grunert I; Wegele H; Haberger M; Bulau P; Leiss M
    J Pharm Biomed Anal; 2020 Jul; 186():113251. PubMed ID: 32251978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen deuterium exchange mass spectrometry in biopharmaceutical discovery and development - A review.
    Deng B; Lento C; Wilson DJ
    Anal Chim Acta; 2016 Oct; 940():8-20. PubMed ID: 27662755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry for structural characterization of therapeutic antibodies.
    Zhang Z; Pan H; Chen X
    Mass Spectrom Rev; 2009; 28(1):147-76. PubMed ID: 18720354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric evaluation of upstream and downstream process influences on host cell protein patterns in biopharmaceutical products.
    Falkenberg H; Waldera-Lupa DM; Vanderlaan M; Schwab T; Krapfenbauer K; Studts JM; Flad T; Waerner T
    Biotechnol Prog; 2019 May; 35(3):e2788. PubMed ID: 30767403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry.
    David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L
    Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimisation of the use of sliding window deconvolution for comprehensive characterisation of trastuzumab and adalimumab charge variants by native high resolution mass spectrometry.
    Millán-Martín S; Carillo S; Füssl F; Sutton J; Gazis P; Cook K; Scheffler K; Bones J
    Eur J Pharm Biopharm; 2021 Jan; 158():83-95. PubMed ID: 33212184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation Analysis of Therapeutic Glycoproteins Produced in CHO Cells.
    Carillo S; Mittermayr S; Farrell A; Albrecht S; Bones J
    Methods Mol Biol; 2017; 1603():227-241. PubMed ID: 28493134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and QC of biopharmaceuticals by MS-based 'multi-attribute method': advantages and challenges.
    Zhang Y; Guo J
    Bioanalysis; 2017 Mar; 9(6):499-502. PubMed ID: 28207284
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the role of current mass spectrometry in pharmaceutical analysis?
    Khalikova M; Jireš J; Horáček O; Douša M; Kučera R; Nováková L
    Mass Spectrom Rev; 2024; 43(3):560-609. PubMed ID: 37503656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping Isomeric Peptides Derived from Biopharmaceuticals Using High-Resolution Ion Mobility Mass Spectrometry.
    Tomczyk N; Giles K; Richardson K; Ujma J; Palmer M; Nielsen PK; Haselmann KF
    Anal Chem; 2021 Dec; 93(49):16379-16384. PubMed ID: 34842410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Native LC-MS for capturing quality attributes of biopharmaceuticals on the intact protein level.
    Füssl F; Strasser L; Carillo S; Bones J
    Curr Opin Biotechnol; 2021 Oct; 71():32-40. PubMed ID: 34157600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MS-based conformation analysis of recombinant proteins in design, optimization and development of biopharmaceuticals.
    Goswami D; Zhang J; Bondarenko PV; Zhang Z
    Methods; 2018 Jul; 144():134-151. PubMed ID: 29678586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Resolution Ion-Mobility-Enabled Peptide Mapping for High-Throughput Critical Quality Attribute Monitoring.
    Arndt JR; Wormwood Moser KL; Van Aken G; Doyle RM; Talamantes T; DeBord D; Maxon L; Stafford G; Fjeldsted J; Miller B; Sherman M
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):2019-2032. PubMed ID: 33835810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.